A cancer vaccine shows its first success and researchers push to widen it
โฎ BeforeCancer vaccines had not yet reached a clear, effective result.
โ
NowAn mRNA cancer vaccine has shown a first success, and work is underway to widen its use.
In short
- The source describes an effective cancer vaccine, reached after about 100 years of effort.
- The next step is testing whether the approach works in more kinds of tumor.
- The source gives no trial numbers, so the scope of the success is not yet clear.
Why it's good news
The source describes this as the first effective cancer vaccine after a century of work. Researchers are now trying to make the approach work across more tumor types. The source does not give trial details, so the strength of the result should be read with that in mind.
Advertisement
From STAT
After 100 years, there's finally an effective cancer vaccine. Now comes the push to get them to work in more tumor types.
Ask this story
๐ The story so far
- 22 Oct 2026 Personalized Cancer Vaccine Cuts Melanoma Recurrence Risk by 42 Percent Where it started.
- 23 Oct 2026 Moderna mRNA vaccine almost halves risk of melanoma returning The same Moderna melanoma vaccine trial result is now described as almost halving recurrence risk, a rephrasing of the earlier 42 percent figure rather than a new development.
- 23 Oct 2026 Personalized mRNA vaccine cuts melanoma recurrence risk in late-stage trial The same personalized mRNA melanoma vaccine's 42% recurrence-risk reduction is now reported from a late-stage trial, with the risk figure restated as death too.
- 23 Oct 2026 Moderna and Merck personalised melanoma vaccine cuts recurrence in trial The same Moderna and Merck melanoma vaccine trial is reported again, now describing delayed return and spread of the cancer in the trial data.
- 23 Oct 2026 Personalised mRNA cancer vaccine cuts melanoma return risk by 42% The same 42% melanoma result is now reported with more detail, adding that it is a Phase III trial of the Keytruda-combined vaccine.
- 24 Oct 2026 Personalized mRNA Vaccine Cuts Melanoma Recurrence by Over 40 Percent The same personalized mRNA melanoma vaccine's Phase 3 trial result is now reported as cutting recurrence risk by over 40 percent.
- 25 Oct 2026 A cancer vaccine shows its first success and researchers push to widen it The personalized mRNA cancer vaccine's melanoma trial success is now seen as a first clear win, and researchers aim to extend it to more tumor types.
- 26 Oct 2026 Personalized mRNA vaccine cuts melanoma return risk in phase 3 trial The same personalized Moderna and Merck melanoma vaccine has now been reported in a phase 3 trial, confirming its effect on recurrence risk.
More like this
Advertisement